AbbVie bets big on Ablynx arthritis candidate
This article was originally published in Scrip
Executive Summary
AbbVie has agreed to pay $175m up front to Belgium firm Ablynx for the anti-IL6R nanobody ALX-0061, which has completed Phase IIa studies for rheumatoid arthritis.